A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer

Inclusion Criteria: * Adults 18 to 75 years of age * Histologically confirmed, poorly differentiated or undifferentiated metastatic nasopharyngeal cancer with at least 1 measurable lesion which has not been irradiated * Ability to swallow and retain oral medication Exclusion Criteria: * Previous cytotoxic chemotherapy except adjuvant, concurrent, or neoadjuvant treatment completed at least 6 months before enrollment * Clinically significant cardiac disease * History of other malignancy within the last 5 years except cured basal cell cancer of the skin or cured cancer in situ of the cervix * Radiotherapy within 4 weeks of treatment start or any prior radiotherapy performed to the indicator lesion(s) being measured in the study